WATCH: Interviews from 67th ASH Annual Meeting 2025

January 6, 2026

VJHemOnc

Long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia: the BRUIN trial

The CaDAnCe-104 trial of BGB-16673 in combination with other agents in R/R B-cell malignancies

SOUNDTRACK-F1: surovatamig plus rituximab vs chemotherapy plus rituximab in previously untreated FL

HealthTree University for Blood Cancers

Can Epcoritamab Improve Outcomes in R-mini-CHOP Patients?

Vumedi

ASH 2025 Insights: Pirtobrutinib in R/R Waldenström Macroglobulinemia – Up to 5 Years of Follow-Up From the Phase 1/2 BRUIN Study

Go to: https://www.vumedi.com/video/ash-2025-insights-pirtobrutinib-in-rr-waldenstrom-macroglobulinemia-up-to-5-years-of-follow-up-from/

ASH 2025 Insights: Epcoritamab + R-mini-CHOP Results in 2-Year Remissions and High MRD Negativity Rates in Elderly Patients With ND DLBCL – Results From the EPCORE NHL-2 Trial

Go to: https://www.vumedi.com/video/ash-2025-insights-epcoritamab-r-mini-chop-results-in-2-year-remissions-and-high-mrd-negativity-rates/